Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 04 - 05 tags : Approval save search
CNS Pharmaceuticals Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2022-04-05 (Crawled : 14:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.63%
H: 1.09%
C: -2.15%
CNSP | News | $0.201 0.95% 0.95% 120K
|
Health Technology
|
| O: 0.24%
H: 29.56%
C: 14.4%
treatment approval berubicin switzerland potential glioblastoma
NanoVibronix Advances Efforts to Achieve NHS Approval
Published: 2022-04-05 (Crawled : 13:00) - biospace.com/
NAOV 4 | $0.7451 -5.68% 6.9K
|
Health Technology
|
| O: -0.85%
H: 1.71%
C: -6.84%
approval
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%
Published: 2022-04-05 (Crawled : 12:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.04%
H: 1.67%
C: 0.91%
treatment opdivo approval nivolumab urothelial carcinoma
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with...
Published: 2022-04-05 (Crawled : 12:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.04%
H: 1.67%
C: 0.91%
treatment opdivo approval nivolumab
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with...
Published: 2022-04-05 (Crawled : 12:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.04%
H: 1.67%
C: 0.91%
treatment opdivo approval nivolumab
Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility
Published: 2022-04-05 (Crawled : 06:00) - globenewswire.com
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.57%
H: 0.79%
C: 0.39%
novartis approval
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.